Friedreich's ataxia: Iron chelators that target the mitochondrion as a therapeutic strategy?

Expert Opinion on Investigational Drugs

Volumn 12, Issue 2, 2003, Pages 235-245

  Richardson, D R ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

2 pyridylcarboxaldehyde isonicotinol hydrazone; Chelators; Desferrioxamine; Friedreich's ataxia; Iron; Iron chelators; Iron overload disease; Pyridoxal isonicotinoyl hydrazone

Indexed keywords

2 FUROYLCARBOXALDEHYDE ISONICOTINOYL HYDRAZONE; 2 PYRIDYLCARBOXALDEHYDE AMINOBENZOYL HYDRAZONE; 2 PYRIDYLCARBOXALDEHYDE BENZOYL HYDRAZONE; 2 PYRIDYLCARBOXALDEHYDE BROMOBENZOYL HYDRAZONE; 2 PYRIDYLCARBOXALDEHYDE HYDROXYBENZOYL HYDRAZONE; 2 PYRIDYLCARBOXALDEHYDE ISONICOTINOYL HYDRAZONE; 2 PYRIDYLCARBOXALDEHYDE THIOPHENECARBOXYL HYDRAZONE; ANTIOXIDANT; CHELATING AGENT; DEFEROXAMINE; FERRITIN; FRATAXIN; HEME; HEMOSIDERIN; HYDRAZINE DERIVATIVE; HYDRAZONE DERIVATIVE; IDEBENONE; IRON; IRON 59; ISONICOTINOYL PICOLINOYL HYDRAZINE; LIGAND; MITOCHONDRIAL PROTEIN; PROTOPORPHYRIN; PYRIDOXAL; PYRIDOXAL FLUOROBENZOYLHYDRAZONE; PYRIDOXAL ISONICOTINOYLHYDRAZONE; PYRIDOXAL METHOXYBENZOUYL HYDRAZONE; SUCCINYLACETONE; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG DESIGN; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENTERIC COATED TABLET; FRIEDREICH ATAXIA; GENE EXPRESSION; GENETIC CODE; GENETIC DISORDER; HUMAN; HYDROPHILICITY; INTRON; IRON CHELATION; IRON METABOLISM; IRON STORAGE; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; SPINOCEREBELLAR DEGENERATION; TRINUCLEOTIDE REPEAT;

EID: 0037317490     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.2.235     Document Type: Review

References (85)

1. PUCCIO H, KOENIG M: Recent advances in the molecular pathogenesis of Friedreich ataxia. Hum. Mol. Genet. (2000) 9:887-892.
2. KOENIG M, MANDEL JL: Deciphering the cause of Friedreich ataxia. Curr. Opin. Neurobiol. (1997) 7:689-694.
3. PANDOLF0 M: Molecular pathogenesis of Friedreich ataxia. Arch. Neurol. (1999) 56:1201-1208.
4. SACHEZ-CASIS G, COTE M, BARBEAU A: Pathology of the heart in Friedreich's ataxia. Can J. Neurol. Sci. (1976) 3:349-354.
5. LAMARCHE JB, SHAPCOTT D, COTE M, LEMIEUX B: Cardiac iron deposits in Friedreich's ataxia. In: Handbook of Cerebellar Diseases. R Lectenberg (Ed.), Dekker, NY (1993):453-457.
6. BABCOCK M, DE SILVA D, OAKS R et al.: Regulation of mitochondrial iron accumulation by Yfh1p, a putative homologue of frataxin. Science (1997) 276:1709-1712.
7. FOURY F, CAZZALINI O: Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett. (1997) 411:373-377.
8. ROTIG A, DE LONLAY P, CHRETIEN D et al.: Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nature Genet. (1997) 17:215-217.
9. WILSON RB, ROOF DM: Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nat. Genet. (1997) 16:352-357.
10. RADISKY DC, BABCOCK MC, KAPLAN J: The yeast frataxin homologue mediates mitochondrial iron efflux: Evidence for a mitochondrial iron cycle. J. Biol. Chem. (1999) 274:4497-4499.
11. WONG A, YANG J, CAVADINI P et al.: The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. (1999) 8:425-430.
12. BECKER E, GREER J, PONKA P, RICHARDSON DR: Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: Characterisation of frataxin expression compared to molecules involved in iron metabolism and hemoglobinisation. Blood (2002) 99:3813-3822.
13. CAMPUZANO V, MONTERMINI L, LUTZ Y et al.: Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet. (1997) 6:1771-1780.
14. KOUTNIKOVA H, CAMPUZANO V, FOURY F, DOLLE P, CAZZALINI O, KOENIG M: Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat. Genet. (1997) 16:345-351.
15. BRADLEY JL, BLAKE JC, CHAMBERLAIN S, THOMAS PK, COOPER JM, SCHAPIRA AHV: Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum. Mol. Genet. (2000) 9:275-282.
16. WALDVOGEL D, VAN GELDEREN P, HALLETT M: Increased iron in the dentate nucleus of patients with Friedreich's ataxia. Ann. Neurol. (1999) 46:123-125.
17. LODI R, COOPER JM, BRADLEY JL et al.: Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl. Acad. Sci. USA (1999) 96:11492-11495.
18. MORGAN RO, NAGLI G, HORROBIN DF, BARBEAU A: Erythrocyte protoporphyrin levels in patients with Friedreich's and other ataxias. Can. J. Neurol. Sci. (1979) 6:227-232.
19. BECKER E, RICHARDSON DR: Frataxin: Its role in iron metabolism and the pathogenesis of Friedreich's ataxia. Int. J. Biochem. Cell Biol. (2001) 33:1-10.
20. EATON JW, QIAN M: Molecular basis of cellular iron toxicity. Free Radic. Biol. Med. (2002) 32:833-840.
21. FOURY F, TALIBI D: Mitochondrial control of iron homeostasis. A genome-wide analysis of gene expression in a yeast frataxin-deficient strain. J. Biol. Chem. (2001) 276:7762-7768.
22. PONKA P: Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood (1997) 89:1-25.
23. PONKA P, NEUWIRT J: Regulation of iron entry into reticulocytes. J. Feedback inhibitory effect of heme on iron entry into reticulocytes and on heme synthesis. Blood (1969) 33:690-707.
24. EBERT P, HESS R, FRYKHOLM B, TSCHNDY D: Succinylacetone, a potent inhibitor of heme synthesis: Effect on cell growth, heme content and aminolevulinic acid dehydratase activity of murine erythroleukemia cells. Biochem. Biophys. Res. Commun. (1979) 88:1382-1390.
25. BOROVA J, PONKA P, NEUWIRT J: Study of intracellular iron distribution in rabbit reticulocytes with normal and inhibited heme synthesis. Biochim. Biophys. Acta (1973) 320:143-156.
26. PONKA P, WILCZYNSKA A, SCHULMAN HM: Iron utilization in rabbit reticulocytes. A study using succinylacetone as an inhibitor of heme synthesis. Biochim. Biophys. Acta (1982) 720:96-105.
27. ADAMS ML, OSTAPIUK I, GRASSO JA: The effects of inhibition of heme synthesis on the intracellular localisation of iron in rat reticulocytes. Biochim. Biophys. Acta. (1989) 1012:243-253.
28. RICHARDSON DR, PONKA P, VYORAL D: Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: Examination of the intermediates involved in iron metabolism. Blood (1996) 87:3477-3488.
29. MÜHLENHOFF U, RICHHARDT N, RISTOW M, KISPAL G, LILL R: The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum. Mol. Genet. (2002) 11:2025-2036.
30. ADAMEC J, RUSNAK F, OWEN WG et al.: Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia. Am. J. Hum. Genet. (2000) 67:549-562.
31. GAKH O, ADAMEC J, GACY AM, TWESTEN RD, OWEN WG, ISAYA G: Physical evidence that yeast frataxin is an iron storage protein. Biochemistry (2002) 41:6798-6804.
32. DHE-PAGANON S, SHIGETA R, CHI Y-I, RISTOW M, SHOELSON SE: Crystal structure of human frataxin. J. Biol. Chem. (2000) 275:30753-30756.
33. MUSCO G, STIER G, KOLMERER B et al.: Towards a structural understanding of Friedreich's ataxia: the solution structure of frataxin. Structure Fold Des. (2000) 8:695-707.
34. HENTZE MW, KÜHN LC: Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. USA (1996) 93:8175-8182.
35. RICHARDSON DR, PONKA P: The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta (1997) 1320:45-57.
36. GOTO Y, PATERSON M, LISTOWSKY I: Iron uptake and regulation of ferritin synthesis by hepatoma cells in hormone-Suppl.ed serum-free medium. J. Biol. Chem. (1983) 258:5248-5255.
37. LEVI S, CORSI B, BOSISOI M et al.: A human mitochondrial ferritin encoded by an intronless gene. J. Biol. Chem. (2001) 276:24437-24440.
38. FRIEND C, SCHER W, HOLLAND JG, SATO T: Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc. Natl. Acad. Sci. USA (1971) 68:378-382.
39. SASSA S: Sequential induction of heme pathway enzymes during erythroid differentiation of mouse Friend leukemia virus-infected cells. J. Exp. Med (1976) 143:305-315.
40. ROSS J, IKAWA Y, LEDER P: Globin messenger-RNA induction during erythroid differentiation of cultured leukemia cells. Proc. Natl. Acad. Sci. USA (1972) 69:3620-3623.
41. ROSS J, SAUTNER D: Induction of globin mRNA accumulation by hemin in cultured erythroleukemic cells. Cell (1976) 8:513-520.
42. PONKA P: Cell biology of heme. Am. J. Med. Sci. (1999) 318:241-256.
43. PONKA P: Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood (1997) 89:1-25.
44. RUSTIN P, VON KLEIST-RETZOW JC, CHANTREL-GROUSSARD K, SIDI D, MUNNICH A, ROTIG A: Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet (1999) 354:477-479.
45. LODI R, HART PE, RAJAGOPALAN B et al.: Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann. Neurol. (2001) 49:590-596.
46. HAUSSE AO, AGGOUN Y, BONNET D et al.: Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart (2002) 87:346-349.
47. PONKA P, BOROVA J, NEUWIRT J, FUCHS O: Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. (1979) 97:317-321.
48. RICHARDSON DR, MOURALIAN C, PONKA P, BECKER E: Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim. Biophys. Acta (2001) 1536:133-140.
49. SMITH JC, KUSHNER JP, BROMBERG M et al.: Evidence for mitochondrial iron overload in patients with Friedreich's ataxia. Proc. Int. Friedreich's Ataxia Conference, Bethesda, Maryland, USA (1999).
50. OLIVIERI NF, BRITTENHAM G: Iron chelating therapy and the treatment of thalassemia. Blood (1997) 89:739-761.
51. MORGAN EH: Chelator-mediated iron efflux from reticulocytes. Biochim. Biophys. Acta (1983) 733:39-50.
52. GARRICK LM, GNIECKO K, LIU Y, COHAN DS, GRASSO JA, GARRICK MD: Iron distribution in Belgrade rat reticulocytes after inhibition of heme synthesis with succinylacetone. Blood (1993) 81:3414-3421.
53. PONKA P, GRADY RW, WILCZYNSKA A, SCHULMAN HM: The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone. Biochim. Biophys. Acta (1984) 802:477-489.
54. HOY T, HUMPHREYS J, JACOBS A, WILLIAMS A, PONKA P: Effective iron chelation following oral adminstration of an isoniazid pyridoxal hydrazone. Br. J. Haematol. (1979) 43:443-449.
55. BRITTENHAM GM: Pyridoxal isonicotinoyl hydrazone: an effective chelator after oral administration. Semin. Hematol. (1990) 27:112-116.
56. RICHARDSON DR, HEFTER GT, MAY PM, WEBB J, RAKER E: Iron chelators of the pyridoxal isonicotinoyl hydrazone class III. Formation constants with calcium(II), magnesium(II), and zinc(II). Biol. Metals (1989) 2:161-167.
57. VITOLO LMW, HEFTER GT, CLARE BW, WEBB J: Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part 2. Formation constants with iron(III) and iron(II). Inorg. Chim. Acta (1990) 170:171-176.
58. RICHARDSON DR, WIS VITOLO ML, HEFTER GT et al.: Iron chelators of the pyridoxal isonicotinoyl hydrazone class part 1. Ionisation characteristics of the ligands and their relevance to biological properties. Inorg. Chim. Acta (1990) 170:165-170.
59. RICHARDSON DR, BAKER E: The release of iron and transferrin by the human malignant melanoma cell. Biochim. Biophys. Acta (1991) 1091:294-302.
60. RICHARDSON DR, PONKA P: The iron metabolism of the human neuroblastoma cell. Lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J. Lab. Clin. Med. (1994) 124:660-671.
61. SAH P: Nicotinoyl and isonicotinoyl hydrazones of pyridoxal. J. Am. Chem. Soc. (1954) 76:300.
62. JOHNSON DK, MURPHY TB, ROSE NJ, GOODWIN WH, PICKART L: Cytotoxic chelators and chelates. 1. Inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper(II) complex of salicylaldehyde benzoyl hydrazone. Inorg. Chim. Acta (1982) 67:159-165.
63. RICHARDSON DR, TRAN E, PONKA P: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood (1995) 86:4295-4306.
64. BECKER E, RICHARDSON DR: Development of novel aroylhydrazone ligands for iron chelation therapy: The 2-pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH) analogues. J. Lab. Clin. Med. (1999) 134:510-521.
65. RICHARDSON DR, PONKA P: Pyridoxal isonicotinoyl hydrazone and its analogues: Potential orally effective iron-chelating agents for the treatment of iron overload disease. J. Lab. Clin. Med. (1998) 131:306-315.
66. RICHARDSON DR, BAKER E, VITOLO LW, WEBB J: Pyridoxal isonicotinoyl hydrazone and analogues. Study of their stability in acid, neutral and basic aqueous solutions by ultraviolet-visible spectrophotometry. Biol. Metals (1989) 2:69-76.
67. PONKA P, EDWARD JT, GAUTHIER M, CHUBB FL, PONKA P: Synthesis of new acylhydrazones as iron-chelating compounds. J. Chem. Eng. Data (1988) 33:538-540.
68. RICHARDSON D, BAKER E, PONKA P, WILAIRAT P, VITOLO ML, WEBB J: Effects of pyridoxal isonicotinoyl hydrazone and analogs on iron metabolism in hepatocytes and macrophages in culture. Birth Defects (1988) 23:81-88.
69. PONKA P, RICHARDSON D, BAKER E, SCHULMAN HM, EDWARD JT: Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim. Biophys. Acta (1988) 967:122-129.
70. BAKER E, RICHARDSON DR, GROSS S, PONKA P: Evaluation of the iron chelation potential of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology (1992) 15:492-501.
71. BLÁHA K, CIKRT M, NERUDOVÁ J, FORNUSKOVÁ H, PONKA P: Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone. Blood (1998) 91:4368-4372.
72. RICHARDSON DR. Iron chelators as therapeutic agents for the treatment of cancer. Crit. Rev. Oncol. Hematol. (2002) 42:267-281.
73. RICHARDSON DR, BECKER E, BERNHARDT PV: The biologically active iron chelators 2-pyridylcarboxaldehyde isonicotinoyl hydrazone, 2-pyridylcarboxaldehyde benzoyl hydrazone and 2-furfural isonicotinoyl hydrazone. Acta Cryst. Sect. C (1999) C55:2102-2105.
74. RICHARDSON DR, BERNHARDT PV, BECKER E: Iron chelators and uses thereof. (2000) International Patent Application No. PCT/AU00/01050.
75. BERNHARDT PV, CHIN P, RICHARDSON DR. Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy. J. Biol. Inorg. Chem. (2001) 6:801-809.
76. XIONG Y, HANNON GJ, ZHANG H, CASSO D, KOBAYASHI R, BEACH D: p21 is a universal inhibitor of cyclin kinases. Nature (1993) 366:701-704.
77. EL-DEIRY WS, TOKINO T, VELCULSECU VE et al.: WAF1, a. potential mediator of p53 tumor suppression. Cell (1993) 75:817-825.
78. AGARWAL ML, AGARWAL A, TAYLOR WR, STARK GR. P53 controls both the G2M and G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA (1995) 92:8493-8497.
79. KASTAN MB, ZHAN Q, EL-DEIRY WS et al.: A mammalian cell cycle check point pathway utilizing p53 and gadd45 is defective in ataxia telangiectasia. Cell (1992) 71:587-597.
80. DARNELL G, RICHARDSON DR. The potential of analogues of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents III: The effect of the ligands on molecular targets involved in proliferation. Blood (1999) 94:781-792.
81. GAO J, RICHARDSON DR: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood (2001) 98:842-50.
82. LOVEJOY DB, RICHARDSON DR: Novel 'hybrid' iron chelators; derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood (2002) 100:666-676.
83. KLAUSNER RD, DANCIS A: A genetic approach to elucidating eukaryotic iron metabolism. FEBS Lett. (1994) 355:109-113.
84. HASSETT R, DIX DR, EIDE DJ, KOSMAN DJ: The Fe(II) permease Fet4p functions as a low affinity copper transporter and supports normal copper trafficking in Saccharomyces cerevisiae. Biochem. J. (2000) 351:477-484.
85. PUCCIO H, SIMON D, COSSEE M et al.: Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. (2001) 27:181-186.